DK1968592T3 - Formuleringer omfattende jorumycin-, renieramycin-, safracin- eller saframycin-relaterede forbindelser og et disaccharid til behandling af proliferative sygdomme - Google Patents

Formuleringer omfattende jorumycin-, renieramycin-, safracin- eller saframycin-relaterede forbindelser og et disaccharid til behandling af proliferative sygdomme

Info

Publication number
DK1968592T3
DK1968592T3 DK06795019.6T DK06795019T DK1968592T3 DK 1968592 T3 DK1968592 T3 DK 1968592T3 DK 06795019 T DK06795019 T DK 06795019T DK 1968592 T3 DK1968592 T3 DK 1968592T3
Authority
DK
Denmark
Prior art keywords
jorumycin
renieramycin
safracin
saframycin
related compounds
Prior art date
Application number
DK06795019.6T
Other languages
English (en)
Inventor
Salve Pilar Calvo
Barreira Maria Tobio
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Application granted granted Critical
Publication of DK1968592T3 publication Critical patent/DK1968592T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK06795019.6T 2005-10-31 2006-10-30 Formuleringer omfattende jorumycin-, renieramycin-, safracin- eller saframycin-relaterede forbindelser og et disaccharid til behandling af proliferative sygdomme DK1968592T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0522082.7A GB0522082D0 (en) 2005-10-31 2005-10-31 Formulations
PCT/GB2006/050362 WO2007052076A2 (en) 2005-10-31 2006-10-30 Formulations comprising jorumycin-, reni eramycin-, safracin- or saframycin-related compounds for treating proliferative diseases

Publications (1)

Publication Number Publication Date
DK1968592T3 true DK1968592T3 (da) 2012-07-02

Family

ID=35515969

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06795019.6T DK1968592T3 (da) 2005-10-31 2006-10-30 Formuleringer omfattende jorumycin-, renieramycin-, safracin- eller saframycin-relaterede forbindelser og et disaccharid til behandling af proliferative sygdomme

Country Status (24)

Country Link
US (1) US9192568B2 (da)
EP (1) EP1968592B1 (da)
JP (1) JP5197373B2 (da)
KR (1) KR101434230B1 (da)
CN (1) CN101300011B (da)
AT (1) ATE549023T1 (da)
AU (1) AU2006310260C1 (da)
CA (1) CA2625096C (da)
DK (1) DK1968592T3 (da)
ES (1) ES2383967T3 (da)
GB (1) GB0522082D0 (da)
HK (1) HK1122743A1 (da)
HR (1) HRP20120478T1 (da)
IL (1) IL190774A (da)
NO (1) NO341057B1 (da)
NZ (1) NZ567291A (da)
PL (1) PL1968592T3 (da)
PT (1) PT1968592E (da)
RS (1) RS52312B (da)
RU (1) RU2429845C2 (da)
SI (1) SI1968592T1 (da)
UA (1) UA97629C2 (da)
WO (1) WO2007052076A2 (da)
ZA (1) ZA200803420B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0708691D0 (en) * 2007-05-04 2007-06-13 Pharma Mar Sa Anticancer treatments a
RU2519750C2 (ru) * 2008-05-16 2014-06-20 Фарма Мар, С.А. Способы лечения множественной миеломы
CN102099025A (zh) * 2008-05-16 2011-06-15 马尔药品公司 Pm00104与另一抗肿瘤剂的联合疗法
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
BR112013027584B1 (pt) 2011-04-28 2020-11-03 Oncopeptides Ab preparação farmacêutica liofilizada de dipeptídeos citotóxicos, método para preparar a mesma e uso de sacarose na dita preparação
BR112015009280B1 (pt) 2012-10-26 2022-05-31 Oncopeptides Ab Preparação farmacêutica liofilizada de melfalana flufenamida, composição e kit de combinação de partes
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2019018539A1 (en) 2017-07-19 2019-01-24 California Institute Of Technology PROCESSES FOR PREPARING COMPOUNDS CONTAINING BIS-TETRAHYDROISOQUINOLINE
WO2022186221A1 (ja) * 2021-03-03 2022-09-09 国立大学法人東京大学 マクロ環含有新規テトラヒドロイソキノリンアルカロイド化合物

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
DE19605212A1 (de) * 1996-02-13 1997-08-14 Basf Ag Phosphordotiertes Silberkatalysator-Festbett
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
CA2288964A1 (en) 1997-05-21 1998-11-26 Genentech, Inc. Novel administration of thrombopoietin
PT1067933E (pt) 1998-04-06 2007-11-15 Univ Illinois Ecteinascidinas semi-sintéticas
HUP0101960A3 (en) 1998-05-11 2003-03-28 Pharma Mar Sa Metabolites of ecteinascidin 743, their use and pharmaceutical compositions containing them
JP2000081438A (ja) 1998-06-25 2000-03-21 Sekisui Chem Co Ltd 被験者の癌化学療法による免疫機能低下の測定方法
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
CZ304749B6 (cs) 2000-04-12 2014-09-24 Pharma Mar, S. A. Ecteinascidin mající pět spojených kruhů s 1,4-můstkem, farmaceutický prostředek, použití a způsob
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
WO2002014554A2 (en) 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
WO2002036145A2 (en) * 2000-10-31 2002-05-10 Pharma Mar, S.A. Kahalalide f formulation
AU3956502A (en) * 2000-11-03 2002-05-27 Harvard College Saframycins, analogues and uses thereof
CZ20031327A3 (cs) 2000-11-06 2003-11-12 Pharma Mar, S. A. Užití ET-743 k výrobě léků pro účinnou protinádorovou léčbu
PL367260A1 (en) 2001-01-25 2005-02-21 Bristol-Myers Squibb Company Parenteral formulation containing epothilone analogs
EP1360337A1 (en) * 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
SK10602003A3 (en) 2001-03-06 2004-10-05 Bristol Myers Squibb Co Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
US20030027799A1 (en) 2001-03-30 2003-02-06 Shire Biochem Inc. Methods of treating cancer using a combination of drugs
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
MXPA04003674A (es) 2001-10-19 2004-07-23 Pharma Mar Sa Uso mejorado de compuesto antitumoral en terapia de cancer.
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US7251892B2 (en) * 2003-07-09 2007-08-07 Temper Corporation Bearing assembly spacer adjustable system and method for adjusting a spacer
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
CA2544320A1 (en) 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Method of treating cancer using a combination comprising et-743 and 5-fluorouracil
JP2007511509A (ja) 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2005118584A2 (en) * 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer
US20080293725A1 (en) 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
EP1812114A2 (en) 2004-09-29 2007-08-01 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti-inflammatory agents
CA2582452C (en) 2004-10-26 2010-09-07 Erard Gilles Pegylated liposomal doxorubicin in combination with ecteinascidin 743
ATE368461T1 (de) * 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
WO2006066183A2 (en) * 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
WO2007062413A2 (en) 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Use of parp-1 inhibitors
JP2009536956A (ja) 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法

Also Published As

Publication number Publication date
CN101300011A (zh) 2008-11-05
SI1968592T1 (sl) 2012-10-30
GB0522082D0 (en) 2005-12-07
PL1968592T3 (pl) 2012-08-31
UA97629C2 (ru) 2012-03-12
KR101434230B1 (ko) 2014-08-26
RS52312B (en) 2012-12-31
US9192568B2 (en) 2015-11-24
RU2429845C2 (ru) 2011-09-27
EP1968592B1 (en) 2012-03-14
CA2625096A1 (en) 2007-05-10
NO20082425L (no) 2008-07-25
HRP20120478T1 (hr) 2012-07-31
HK1122743A1 (en) 2009-07-17
PT1968592E (pt) 2012-06-18
CN101300011B (zh) 2011-12-28
ES2383967T3 (es) 2012-06-27
JP2009513618A (ja) 2009-04-02
EP1968592A2 (en) 2008-09-17
WO2007052076A3 (en) 2008-03-20
NZ567291A (en) 2011-04-29
AU2006310260A1 (en) 2007-05-10
AU2006310260C1 (en) 2013-09-19
NO341057B1 (no) 2017-08-14
KR20080064959A (ko) 2008-07-10
RU2008121716A (ru) 2009-12-10
ZA200803420B (en) 2009-10-28
IL190774A (en) 2013-11-28
US20090076016A1 (en) 2009-03-19
AU2006310260B2 (en) 2012-08-09
CA2625096C (en) 2015-11-24
ATE549023T1 (de) 2012-03-15
WO2007052076A2 (en) 2007-05-10
IL190774A0 (en) 2008-11-03
JP5197373B2 (ja) 2013-05-15

Similar Documents

Publication Publication Date Title
DK1968592T3 (da) Formuleringer omfattende jorumycin-, renieramycin-, safracin- eller saframycin-relaterede forbindelser og et disaccharid til behandling af proliferative sygdomme
TW200621256A (en) Formulations
DK1765391T3 (da) Bakterielle præparater til behandlingen af cancer
DK1836169T3 (da) Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
CR8986A (es) Isoxazoles sustituidos como fungicidas
DK2026803T3 (da) Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf
DK1926582T3 (da) Fremgangsmåder til beredning af læder
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
MX2009004030A (es) Articulos antimicrobianos y metodos de fabricacion.
NO20072473L (no) Fremgangsmate for fremstilling av kinolinforbindelser og oppnadde produkter
DK1881830T3 (da) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-derivater til behandling af infertilitet
BRPI0615141A2 (pt) inibidores pentacìclicos de quinase
DK1838683T3 (da) Fremgangsmåde til fremstilling af [1,4,5]-oxadiazepinderivater
DK2185561T3 (da) Derivater af 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6-carboxamid og 2,3,4,5-tetrahydroprrolo(1,2-a)-diazepin-7-carboxamid, fremstilling deraf og terapeutisk anvendelse deraf
DK1727792T3 (da) Fremgangsmåde til fremstilling af semicarbazoner
TW200738236A (en) Certain chemical entities, compositions, and methods
GB0515025D0 (en) Organic compounds
ATE489368T1 (de) Pyrimidinonverbindungen als calcilytica
DK1786913T3 (da) Fremgangsmåde til fremstilling af diarylcycloalkylderivater
ECSP077378A (es) Isoxazoles sustituidos como fungicidas
DK1735297T3 (da) Fremgangsmåde til fremstilling af benzoxathiepinderivater
DK1787644T3 (da) Otologisk opløsning og fremgangsmåde til dennes fremstilling